Carl Pabo

Carl joined +ND Capital in 2008. His research in biophysics made him a world leader in issues involving the structure and design of DNA-binding proteins. Dr. Pabo was a Professor at the Johns Hopkins University School of Medicine (1982-1991) and at the Massachusetts Institute of Technology (1991-2001), and an investigator with the Howard Hughes Medical Institute (1986-2001). He was Chief Scientific Officer at Sangamo BioSciences from 2001-2003. More recently, Dr. Pabo’s work has focused on “long-range strategic thinking,” developing fresh ways of addressing some of the most pressing technical and social challenges of the modern age. While working on these projects, he has held appointments as a Visiting Professor at Caltech, Stanford, Berkeley, and Harvard; and has been supported by a Guggenheim Fellowship.  He now runs Humanity 2050 (a non-profit focusing on key global challenges), and he is a member of the US National Academy of Sciences and of the American Academy of Arts and Sciences.

Carl received his BS in Biochemistry and Biophysics from Yale in 1974 and received his PhD in Biochemistry from Harvard in 1980.